What is this paper about
This paper shows that GLP-1 receptor agonists are no longer just diabetes or weight-loss drugs: across a broad evidence base, they emerge as major cardiometabolic therapies linked to lower cardiovascular risk through both metabolic and direct vascular effects. The full paper is worth reading because it shows where this benefit is strongest, where the evidence is still mixed, and why the biggest gap may now lie not in efficacy, but in getting these drugs to the patients who need them most.
